Home › Research › Biomarkers
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Leslie M. Shaw, Hugo Vanderstichele, Malgorzata Elzbieta Knapik-Czajka, Christopher M. Clark, Paul S. S. Aisen, Ronald Carl Petersen, Kaj Blennow, Holly D Soares et al.. Annals of Neurology, 2009-03-19
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
CSF A beta(1-42) was the most sensitive biomarker for AD in the autopsy cohort of CSF samples: receiver operating characteristic area under the curve of 0.913 and sensitivity for AD detection of 96.4%. In the ADNI cohort, a logistic regression model for A beta(1-42), t-tau, and APO epsilon 4 allele count provided the best assessment delineation of mild AD. An AD-like baseline CSF profile for t-tau/A beta(1-42) was detected in 33 of 37 ADNI mild cognitive impairment subjects who converted to probable AD during the first year of the study. The CSF biomarker signature of AD defined by A beta(1-42) and t-tau in the autopsy-confirmed AD cohort and confirmed in the cohort followed in ADNI for 12 months detects mild AD in a large, multisite, prospective clinical investigation, and this signature appears to predict conversion from mild cognitive impairment to AD.
What this study adds
Evidence grade: Moderate
In an autopsy cohort, cerebrospinal fluid amyloid-beta 1-42 was the most sensitive biomarker for Alzheimer's disease, with 96.4% sensitivity for detection. Reported effect size: 96.4%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M. E., Clark, C. M., Aisen, P. S. S., Petersen, R. C., et al. (2009). Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology. https://doi.org/10.1002/ana.21610
Vancouver
Shaw LM, Vanderstichele H, Knapik-Czajka ME, Clark CM, Aisen PSS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology. 2009. doi:10.1002/ana.21610. PMID: 19296504.
BibTeX
@article{shaw2009-19296504,
author = {Shaw, Leslie M. and Vanderstichele, Hugo and Knapik-Czajka, Malgorzata Elzbieta and Clark, Christopher M. and Aisen, Paul S. S. and Petersen, Ronald Carl and Blennow, Kaj and Soares, Holly D and others},
title = {{Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects}},
journal = {Annals of Neurology},
year = {2009},
doi = {10.1002/ana.21610},
pmid = {19296504},
url = {https://doi.org/10.1002/ana.21610}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- CSF A beta(1-42) was the most sensitive biomarker for AD in the autopsy cohort of CSF samples: receiver operating characteristic area under the curve of 0.913 and sensitivity for AD detection of 96.4%.
- In the ADNI cohort, a logistic regression model for A beta(1-42), t-tau, and APO epsilon 4 allele count provided the best assessment delineation of mild AD.
- An AD-like baseline CSF profile for t-tau/A beta(1-42) was detected in 33 of 37 ADNI mild cognitive impairment subjects who converted to probable AD during the first year of the study.
- The CSF biomarker signature of AD defined by A beta(1-42) and t-tau in the autopsy-confirmed AD cohort and confirmed in the cohort followed in ADNI for 12 months detects mild AD in a large, multisite, prospective clinical investigation, and this signature appears to predict conversion from mild cognitive impairment to AD.
Why it matters
In an autopsy cohort, cerebrospinal fluid amyloid-beta 1-42 was the most sensitive biomarker for Alzheimer's disease, with 96.4% sensitivity for detection. In the ADNI cohort, an Alzheimer's-like baseline cerebrospinal fluid profile was detected in 33 of 37 mild cognitive impairment subjects who converted to probable Alzheimer's disease during the first year, suggesting the signature may predict conversion.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Effect size96.4%
- Evidence strengthModerate
How this study scored 67/100
Published in a leading specialty journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 64 of the 96 points we could judge it on, which is 67 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Annals of Neurology) |
| Journal's citation record | 3 / 4 | Annals of Neurology: journal h-index 437 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2009 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 2,069 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 108.9 citations a year over 19 year(s) since 2009 |
| Impact for its field and year | 6 / 6 | Cited 76.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 6 / 6 | Cited by 248 other studies in this library |
| Still being cited | 4 / 4 | Cited 251 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | University of Pennsylvania: institution h-index 1,859 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19296504) |
| Free to read | 2 / 2 | Free to read |
| Points | 64 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 64 of the 96 points we could judge it on is 67 out of 100. |
| Total | 67 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
248 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.